by Backoffice | Nov 30, 2022 | Trial results
The Danish Medicines Agency has November 23rd, 2022, approved the un-blinded phase I dose-titrating clinical trial where children with autism and signs of leaky gut syndrome are treated with allogeneic adipose-derived mesenchymal stem cells (ASCs). The children will...
by Backoffice | Nov 4, 2022 | Studies and testing
The Danish National Center for Ethics has November 2nd, 2022, approved the un-blinded phase I clinical trial with dose-titrating of allogeneic adipose-derived mesenchymal stem cells (ASCs) for treatment of children with autism. The project is a collaboration between...
by Backoffice | Sep 21, 2022 | Studies and testing
Cell2Cure will be investigating treatment of patients with diabetic foot ulcus with C2C_ASC. The clinical study will be carried out in collaboration with Professor Ole Lander Svendsen and his team at Bispebjerg University Hospital, Copenhagen, Denmark. The study was...
by Backoffice | Aug 21, 2022 | Patents
As of the 24th of March 2022, the patent secures C2Cs technological concept for industrial production, upscaling, and distribution of ASC products in Australia (Patent number: 2016342387). The patent “STEM CELL THERAPY BASED ON ADIPOSE-DERIVED STEM CELLS” has...
by Backoffice | Jun 17, 2022 | Studies and testing
Aqueous Deficient Dry Eye Disease, Sjögren’s syndrome is a serious autoimmune disease that can cause serious eye and vision problems due to reduced tear production. The patient enrollment is now finalized in the randomized double-blind placebo-controlled phase II...
Recent Comments